This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Assistance Publique-Hopitaux De Paris, Biomedical Research Foundation of the Academy of Athens, Commissariat a L'energie Atomique Et Aux Energies Alternatives. Active years: 2022.
Company Filing History:
1 out of 331 
1 out of 4 
1 out of 8,816 
Years Active: 2022
Title: Ieronimos Zoidakis: Innovator in Cancer Diagnosis
Introduction
Ieronimos Zoidakis is a notable inventor based in Athens, Greece. He has made significant contributions to the field of cancer diagnosis through his innovative research and patented inventions. His work focuses on the development of biomarker proteins that can aid in the diagnosis and prognosis of bladder cancer.
Latest Patents
Zoidakis holds a patent for "Bladder cancer biomarker proteins." This invention relates to a collection of signature peptides representing at least 10 proteins for use in cancer diagnosis and/or prognosis. It also includes an artificial protein comprising these signature peptides and a nucleic acid construct encoding for such an artificial protein. Furthermore, the invention outlines a method for cancer diagnosis and/or prognosis that involves analyzing at least 10 proteins in a urine sample from a subject. Additionally, it features an immunoassay product that comprises antibodies for detecting at least 10 proteins.
Career Highlights
Throughout his career, Ieronimos Zoidakis has worked with various organizations, including Polyquant GmbH and Commissariat à l'Énergie Atomique et aux Énergies Alternatives. His experience in these companies has contributed to his expertise in the field of cancer research and diagnostics.
Collaborations
Zoidakis has collaborated with notable professionals in his field, including Jerome Garin and Christophe Masselon. These collaborations have further enhanced his research and development efforts in cancer biomarker technologies.
Conclusion
Ieronimos Zoidakis is a pioneering inventor whose work in bladder cancer biomarker proteins has the potential to significantly impact cancer diagnosis and prognosis. His contributions to the field exemplify the importance of innovation in medical research.